PAULINA CHMIEL^1,2, ALEKSANDRA SłOWIKOWSKA^1,2, ŁUKASZ BANASZEK^1,2, ANNA SZUMERA-CIEćKIEWICZ³, BARTłOMIEJ SZOSTAKOWSKI¹, MATEUSZ J. SPAłEK^1,4,*, TOMASZ ŚWITAJ¹, PIOTR RUTKOWSKI¹, ANNA M. CZARNECKA¹

Oncology Research, Vol.32, No.7, pp. 1141-1162, 2024, DOI:10.32604/or.2024.050350 - 20 June 2024

Abstract Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult… More >

CONSTANTINE N. LOGOTHETIS¹, NATHAN P. HORVAT², TONY KURIAN³, CELESTE BELLO³, JULIO CHAVEZ³, LEIDY ISENALUMHE³, BIJAL SHAH³, LUBOMIR SOKOL³, HAYDER SAEED³, JAVIER PINILLA³, SAMEH GABALLA^3,*

Oncology Research, Vol.32, No.6, pp. 1031-1036, 2024, DOI:10.32604/or.2024.046885 - 23 May 2024

Abstract Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin’s lymphomas. Only one trial has evaluated frontline BR prospectively in EMZL. This retrospective study reports outcomes among EMZL patients receiving frontline BR. Twenty-five patients were included with a median age of 69 years (40–81). Five (20.0%) patients had stage I/II disease, and 20 (80.0%) had stage III/IV disease. The median number of cycles was 6.0 (3.0–6.0). Maintenance rituximab was administered to 10 (41.7%) individuals. Overall response rate (ORR) was More >

JIYU WANG^1,#, LIUYING YI^2,#, KEKE HUANG¹, YANGYANG WANG¹, HUIPING WANG¹, ZHIMIN ZHAI^1,*

BIOCELL, Vol.48, No.3, pp. 453-462, 2024, DOI:10.32604/biocell.2024.047871 - 15 March 2024

Abstract Background: The primary cause of treatment failure in patients with refractory or relapsed B-cell non-Hodgkin lymphoma (r/r B-NHL) is resistance to current therapies, and therapy-induced senescence (TIS) stands out as a crucial mechanism contributing to tumor drug resistance. Here, we analyzed SENEX/Rho GTPase Activating Protein 18 (ARHGAP18) expression and prognostic significance in doxorubicin-induced B-NHL-TIS model and r/r B-NHL patients, investigating its target in B-NHL cell senescence and the effect of combining specific inhibitors on apoptosis resistance in B-NHL-TIS cells. Methods: Raji cells were transfected with the human SENEX shRNA recombinant lentiviral vector (Sh-SENEX) and the empty vector… More >

ZHENG CAO^1,#, CHUNXIAO ZHOU^1,#, ZHIMIN WU¹, CHUNYAN WU¹, WEN ZHANG¹, SHILV CHEN¹, XINDONG ZHAO¹, SHAOLING WU^2,*

BIOCELL, Vol.47, No.5, pp. 1075-1083, 2023, DOI:10.32604/biocell.2023.027027 - 10 April 2023

Abstract Background: Dihydroartemisinin (DHA) is reported to be a potential anticancer agent, and the mechanisms underlying the effects of DHA on diffuse large B cell lymphoma however are still obscure. This study aimed to assess the antitumor effect of DHA on diffuse large B cell lymphoma cells and to determine the potential underlying mechanisms of DHA-induced cell apoptosis. Methods: Here, the Cell Counting Kit 8 assay was conducted to study cell proliferation. We performed Annexin V-FITC/propidium iodide staining, real-time polymerase chain reaction, and western blot analysis to analyze cell apoptosis and potential molecular mechanisms. Results: The results showed More >

Roberto Altieri^1,2,*, Francesco Certo¹, Marco Garozzo¹, Giacomo Cammarata¹, Massimiliano Maione¹, Giuseppa Fiumanò³, Giuseppe Broggi⁴, Giada Maria Vecchio⁴, Rosario Caltabiano⁴, Gaetano Magro⁴, Giuseppe Barbagallo¹

Oncologie, Vol.24, No.4, pp. 693-706, 2022, DOI:10.32604/oncologie.2022.025393 - 31 December 2022

Abstract Background: Intracranial lymphoma remains a challenging differential diagnosis in daily neurosurgical practice. We analyzed our early experience with a surgical series of frameless neuronavigated biopsies in Primary CNS Lymphomas (PCNSLs), highlighting the importance of using an intraoperative combined imaging protocol (5-ALA fluorescence, i-CT and ¹¹C-MET-PET) to overcome potential targeting errors secondary to tumor volume reduction after corticosteroid therapy. Materials and Methods: All patients treated for PCNLSs at our center in a 24-month period (1/1/2019 to 31/12/2020) were analyzed. Our cohort included 6 patients (4 males), with a median age of 67 years (59–82). A total of 45 samples… More >

Schahrazad Soltane^*, Sameer Alsharif , Salwa M.Serag Eldin

Computer Systems Science and Engineering, Vol.40, No.2, pp. 629-644, 2022, DOI:10.32604/csse.2022.019333 - 09 September 2021

Abstract Current cancer diagnosis procedure requires expert knowledge and is time-consuming, which raises the need to build an accurate diagnosis support system for lymphoma identification and classification. Many studies have shown promising results using Machine Learning and, recently, Deep Learning to detect malignancy in cancer cells. However, the diversity and complexity of the morphological structure of lymphoma make it a challenging classification problem. In literature, many attempts were made to classify up to four simple types of lymphoma. This paper presents an approach using a reliable model capable of diagnosing seven different categories of rare and… More >

Yongtao Yu, Guangdong Zou^*

Oncologie, Vol.23, No.2, pp. 293-301, 2021, DOI:10.32604/Oncologie.2021.015520 - 22 June 2021

Abstract Objective: The purpose was to explore the value of multi-slice spiral CT (MSCT) multiplanar reconstruction technique in the diagnosis and clinicopathological analysis of gastrointestinal lymphoma (GIL). Methods: 82 GIL patients treated in our hospital from February 2018 to February 2019 were selected as the experimental group of this study, and 82 patients with other gastrointestinal tumors diagnosed by pathology during the same period were selected as the control group. Both groups of patients were scanned by MSCT and analyzed by multiplanar reconstruction technique to compare the diagnostic results and clinicopathological indexes of the two groups. Results: The… More >

JIYU WANG^#, YING PAN^#, YANG WAN, ZHIXIANG WANYAN, ZHITAO WANG, QIANSHAN TAO, ZHIMIN ZHAI^*

BIOCELL, Vol.45, No.4, pp. 933-942, 2021, DOI:10.32604/biocell.2021.014280 - 22 April 2021

Abstract The present study aimed to clarify the role of SENEX in malignant cell proliferation in diffuse large B-cell lymphoma (DLBCL). 22 DLBCL patients (6 newly diagnosed cases, 7 cases at complete remission, and 9 relapsed cases) were included in the study. Our results indicated that both SENEX gene and protein were significantly increased in peripheral blood mononuclear cells (PBMCs) and tumor cells of relapsed DLBCL patients, accompanied by overexpression of p21, p16, and phosphorylated retinoblastoma (Rb). Silencing the SENEX gene in a DLBCL cell line caused a significant decrease in cell proliferation and inhibited cell cycle progression More >

Xiaolin Wu, Lanping Diao, Guimin Zhao, Chen Huang, Yingzhen Yao, Zhe Gao, Lili Wu^*

Oncologie, Vol.23, No.1, pp. 141-148, 2021, DOI:10.32604/Oncologie.2021.014790 - 30 March 2021

Abstract This study aimed to investigate the relationship and diagnostic potential between microsatellite instability (MSI) caused by a 9-bp GGGGGTAGA insertion/deletion in mitochondrial DNA (mtDNA) at position 8272 and clinical features in Chinese patients diagnosed with non-Hodgkin’s lymphoma. The 9-bp GGGGGTAGA insertion/deletion in the non-d-loop area of the mitochondrial DNA at the 8272 locus was detected by PCR in 139 non-Hodgkin’s lymphoma patient samples. GGGGGTAGA insertion/deletion was found in a total of 16 cases (11.5%), including nine T cell lymphoma and seven B cell lymphoma cases. The 5-year survival rate was 33.3% in patients with non-Hodgkin’s More >

Qiuyun Luo^*†1, Wentao Pan^*†‡1, Suna Zhou^*†1, Guangfeng Wang^‡, Hanjie Yi^*§, Lin Zhang^*¶, Xianglei Yan^*†, Luping Yuan^*†, Zhenyi Liu^#, Jing Wang^**, Haibo Chen^#, MiaoZhen Qiu^*††, DaJun Yang^*†‡, Jian Sun^*‡‡

Oncology Research, Vol.28, No.4, pp. 331-344, 2020, DOI:10.3727/096504020X15825405463920

Abstract Despite therapeutic advances, the effective treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains a major clinical challenge. Evasion of apoptosis through upregulating antiapoptotic B-cell lymphoma-2 (BCL-2) family members and p53 inactivation, and abnormal activation of B-cell receptor signaling pathway are two important pathogenic factors for DLBCL. In this study, our aim is to explore a rational combination of BCL-2 inhibitor plus Bruton’s tyrosine kinase (BTK) blockade or p53 activation for treating DLBCL with the above characteristics. We demonstrated that a novel BCL-2 selective inhibitor APG-2575 effectively suppressed DLBCL with BCL-2 high expression… More >